Company news
Humacyte, Inc. (NASDAQ:HUMA) news
Humacyte, Inc. news releases on 6ix. Latest, Apr 11, 2023: Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis…
Press releases — page 3
Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients
April 10, 2023
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
March 23, 2023
Humacyte Third Quarter 2022 Financial Results and Business Update
November 9, 2022
Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting
September 22, 2022
Humacyte Expands Board of Directors and Leadership Team with New Appointments
September 19, 2022
Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress
September 8, 2022
Humacyte Second Quarter 2022 Financial Results and Business Update
August 11, 2022
Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting
July 24, 2022
Humacyte Announces Presentation of Preclinical Data on the HAV™ in Coronary Artery Bypass Grafting at the Basic Cardiovascular Sciences Scientific Sessions
July 18, 2022
Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options
June 28, 2022
Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D.
June 26, 2022
Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel™ (HAV™) for Repair of Vascular Trauma Injuries
June 20, 2022
Humacyte Presents New Immunogenicity Data on Human Acellular Vessels™ (HAVs™)
June 7, 2022
Humacyte First Quarter 2022 Financial Results and Business Update
May 12, 2022
Humacyte to Provide Human Acellular Vessels™ (HAVs™) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries
May 8, 2022
Humacyte Expands Leadership Team with Appointment of Shamik Parikh, M.D., as Chief Medical Officer
April 4, 2022
Humacyte Announces Date of Annual Shareholder Meeting
April 3, 2022
Humacyte Reports Fourth Quarter and Year End 2021 Financial Results and Provides Business Update
March 28, 2022
Humacyte to Present Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022
March 20, 2022
Humacyte Announces Publication of Positive Long-Term Follow-Up Data from Phase 2 Trial of HAV™ for Hemodialysis
February 27, 2022
Humacyte Announces Clinical Case Series Demonstrating Potential of Human Acellular Vessel™ (HAV™) to Expand Opportunities for Limb Salvage in Multiple Complex Vascular Reconstruction Scenarios
January 30, 2022
Humacyte Announces Preclinical Results of Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting
January 27, 2022
Humacyte Announces Presentation of First Eight Expanded Access Cases Using Human Acellular Vessel™ (HAV) for Treatment of Critical Limb Ischemia at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society
January 5, 2022
Humacyte Announces Presentation of First Preclinical Results of the HAV™ in Coronary Artery Bypass Grafting at Advanced Therapies Week Conference
January 3, 2022
Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles
December 30, 2021
Humacyte Announces Publication Highlighting the First Use of the Human Acellular Vessel (HAV™) as Arterial Bypass Conduit for Replacement of Infected Prosthetic Graft
December 14, 2021
Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at American Heart Association’s Scientific Sessions 2021
November 15, 2021
Humacyte Presents New 12-Month Data from HAVs™ Produced Using Commercial-Scale Manufacturing System
November 14, 2021
Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights
November 11, 2021
Humacyte Announces Issuance of Three Additional U.S. Patents Covering its Proprietary Universally Implantable Bioengineered Human Tissue Platform
September 19, 2021